RELMADA THERAPEUTICS, INC. — Director's Dealing 2018

Apr 3, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2018-04-02

Reporting Person: Vitolo Ottavio V. (Chief Medical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants to purchase common stock	$0.80	2027-06-27	Common Stock (150000)		Direct
Options to purchase common stock	$0.88	2028-04-02	Common Stock (300000)		Direct

Footnotes

F1: Warrants 100% vested on date of grant.

F2: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, a total of 25% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal increments of 6.25% per quarter of the initial option grant over the following three year period.